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Background: High-sensitivity cardiac troponin I (hs-cTnI) and the soluble isoform of sup-
pression of tumorigenicity 2 (sST2) are useful prognostic biomarkers in acute coronary 
syndrome (ACS). The aim of this study was to test the short term prognostic value of sST2 
compared with hs-cTnI in patients with chest pain. 
Methods: Assays for hs-cTnI and sST2 were performed in 157 patients admitted to the 
Emergency Department (ED) for chest pain at arrival. In-hospital and 30-day follow-up 
mortalities were assessed.
Results: The incidence of ACS was 37%; 33 patients were diagnosed with ST elevation 
myocardial infarction (STEMI), and 25 were diagnosed with non-ST elevation myocardial 
infarction (NSTEMI). Compared with the no acute coronary syndrome (NO ACS) group, 
the median level of hs-cTnI was higher in ACS patients: 7.22 (5.24-14) pg/mL vs 68 (15.33 
-163.50) pg/mL (P <0.0001). In all patients, the sST2 level at arrival showed higher inde-
pendent predictive power than hs-cTnI (odds ratio [OR] 20.13, P <0.0001 and OR 2.61, 
P <0.0008, respectively). sST2 at ED arrival showed a greater prognostic value for cardio-
vascular events in STEMI (area under the curve [AUC] 0.80, P <0.001) than NSTEMI pa-
tients (AUC 0.72, P <0.05). Overall, 51% of the STEMI patients with an sST2 value>35 
ng/mL at ED arrival died during the 30-day follow-up.
Conclusions: sST2 has a greater prognostic value for 30-day cardiac mortality after dis-
charge in patients presenting to the ED for chest pain compared with hs-cTnI. In STEMI 
patients, an sST2 value >35 ng/mL at ED arrival showed the highest predictive power for 
short-term mortality.
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INTRODUCTION
The majority of patients with acute coronary syndrome (ACS) 
present to the emergency department (ED) because of chest 
pain [1], and both prompt diagnosis and risk stratification are 
crucial to start an appropriate treatment [2]. Therefore, applica-
tion of current guidelines [1, 3, 4] with the use of high-sensitivity 
cardiac troponin I (hs-cTnI) measurement helps to expedite the 
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ACS distribution of myocardial infarction and rule out differential 
distribution [5-7]. hs-cTnI assays represent an important advance 
with added sensitivity for cardiac myocyte necrosis [8, 9]. 
Along with its diagnostic role for risk stratification in acute car-
diac conditions, hs-cTnI can provide prognostic information on 
stable disease states. In addition, accurate risk stratification for 
the possible development of in-hospital death or other severe 
life-threatening complications is desirable. High-sensitivity Tro-
ponins assays can detect minute levels of myocyte necrosis 
[10]. Moreover, there are several proposed mechanisms of tro-
ponin release that are not related to necrosis, including apopto-
sis, cellular release of proteolytic products, increased cell wall 
permeability with stress or stretch, and the production of mem-
branous blebs that contain troponin [11]. Although the conven-
tional sensitivity assays are specific for myocyte necrosis, hs-cTnI 
assays also show high specificity. Furthermore, there is a consid-
erable amount of evidence to indicate that increasing values of 
hs-cTnI (and perhaps changes in values over time) correlate 
with the risk of adverse cardiac events [12, 13]. There is an in-
ternational consensus on the role of elevated troponins as pre-
dictors of adverse outcomes in patients with ACS during short- 
and long-term follow-ups [14]. One study showed that troponin 
measured with a high-sensitivity assay was a more robust pre-
dictor of cardiovascular death at 1-yr follow-up in patients pre-
senting to the ED with chest pain compared with the conven-
tional troponin assay [15]. 
Furthermore, the soluble isoform of suppression of tumorige-
nicity 2 (sST2) has been proposed as a prognostic marker of 
mortality in patients with ACS [16-23]. Circulating sST2 levels 
appear to be linked to the presence of adverse cardiac remodel-
ing due to tissue fibrosis overproduction in response to ACS [17, 
18]. Indeed, sST2 elicits a cardio-protective response to cardiac 
disease or injury such as an acute cardiac ischemic event [19, 
20]. The loss of a correct transduction of interleukin (IL)-33/ST2L 
signaling leads to uncontrolled cardiac remodeling accompanied 
by hypertrophy of the myocytes and fibrosis with worsening of 
left ventricular function [24]. As a result, the heart is subjected 
to greater stress in the presence of high levels of sST2; thus, high 
levels of sST2 are associated with an increased risk of mortality 
in patients with myocardial infarction [18, 21-23]. The predic-
tive role of sST2 for risk of death in ACS differs between patients 
diagnosed with non-ST elevation myocardial infarction (NSTEMI) 
and ST elevation myocardial infarction (STEMI) and between 
assessments of short-term (30-day) and long-term (>1 yr) fol-
low ups [16-18, 25]. However, there are no data available on 
the value of sST2 compared with hs-cTnI measurements on ED 
admission for the prediction of early cardiovascular-related death. 
Therefore, the aims of this study were first to evaluate the prog-
nostic roles of circulating levels of sST2 and hs-cTnI for the 30-
day mortality in patients presenting to the ED with chest pain, 
and then to compare the prognostic role of sST2 and hs-cTnI in 
the STEMI and NSTEMI patient subgroups. In addition, the pro-
posed sST2 cut-off point of >35 ng/mL as a prognostic risk fac-
tor in heart failure [26] was evaluated. Overall, this study should 
help to best identify ACS patients with a high risk of short-term 
cardiovascular-related death.
METHODS
This was a prospective observational study performed in the ED 
of Sant’Andrea Hospital in Rome, Italy, from January 2012 to 
January 2013. The study was approved by Ethical Committee of 
Sant’Andrea Hospital. A total of 157 (110 men/47 women) pa-
tients presenting to the ED for chest pain were enrolled. Ten pa-
tients were lost to follow-up (they did not answer the phone call; 
three were NSTEMI patients and seven were NO ACS patients). 
Overall, the incidence of ACS was 37% (58 patients). In the ACS 
group, 57% (33 patients) had STEMI and 43% (25 patients) 
had NSTEMI. During the 30-day follow-up, of the 147 patients, 
30 (20%) died (23 ACS, 7 NO ACS), and 117 (80%) were still 
alive. In the STEMI and NSTEMI groups, 12 and 11 patients had 
cardiovascular-related deaths at 30 days, respectively. 
Patients’ characteristics are described in Table 1.The inclu-
sion criteria were: chest pain at rest, chest pain with effort, and 
atypical chest pain with a cardiovascular risk. The exclusion cri-
teria were: chest pain due to trauma, chest pain associated with 
osteomuscular movements, and burning chest pain without car-
diovascular risk. Each patient meeting the inclusion criteria was 
assigned a yellow code at admission. The mean time of presen-
tation to the ED from the start of symptoms was 2 hr. The mean 
time elapsed after the assignment of the yellow code to the tri-
age work station was 5 min. The following parameters were ex-
amined and recorded for each patient at admission in the ED: 
anamnestic data, physical examination, evaluation of vital pa-
rameters, venous blood sample for routine laboratory exams (in-
cluding hs-cTnI at admission and at 2 hr after admission), and 
for detection of copeptin, sST2, neutrophil gelatinase-associated 
lipocalin (NGAL), and brain natriuretic peptide (BNP), chest X-
rays. Electrocardiogram (EKG) was performed within 10 min af-
ter ED arrival. The management of patients with chest pain was 
performed according to the European Society of cardiology 
(ESC) guidelines for the management of ACS and chest pain, 
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and any significant treatment modality between favorable and 
unfavorable groups was performed according to these guide-
lines [1, 3, 4, 27]. A 30-day follow-up phone call was made with 
the aim of recording any adverse cardiovascular-related events 
(death) that occurred after discharge. On the basis of the final 
diagnosis, patients were subdivided into two groups: ACS and 
NO ACS groups. ACS patients were further subdivided into pa-
tients diagnosed with STEMI and those diagnosed with NSTEMI. 
The in-hospital management of ACS was performed according 
to current guidelines [1, 3, 4].
1. sST2 assay
A peripheral venous blood sample was taken from each patient, 
which was collected in heparinized tubes and spun for 15 min 
at 3,500g with cooling during centrifugation. Samples were sep-
arated into 500-μL aliquots and immediately frozen at -40°C 
until the assay was performed. The sST2 assay (Presage ST2 
Assay, Critical Diagnostics, San Diego, CA, USA) is a quantita-
tive sandwich monoclonal ELISA [28]. Diluted plasma (diluted 
50-fold with the sample diluent) was loaded into appropriate 
wells in an anti-ST2 antibody-coated plate and incubated for the 
prescribed time. Following a series of steps in which the reagents 
were washed from the plate, and additional reagents were added 
and subsequently washed out, the analyte was finally detected 
by the addition of a colorimetric reagent, and the resulting signal 
was measured spectroscopically at 450 nm. According to the 
manufacturer instructions, the 99th percentile of the cut-off is 
18.8 (14.5-25.3) ng/mL. The coefficient of variation (CV) of the 
assay is about 5% [28]. 
2. hs-cTnI assay
Peripheral venous blood samples were withdrawn from each 
patient, and the 10-mL blood samples in heparinized tubes were 
sent to our central hospital laboratory for measurement of hs-
cTnI, which is a routine screening diagnostic test performed in 
real time at our ED for suspected cases of ACS. The ARCHITECT 
STAT High Sensitive Troponin I assay (Abbott Laboratories, Ab-
bott Park, IL, USA) is a chemiluminescent microparticle immu-
noassay for the in vitro quantitative determination of cardiac tro-
ponin I, and can be used with the Abbott ARCHITECT i2000SR 
and i1000SR analyzers [29]. Results are available within 16 min. 
The ARCHITECT STAT High Sensitive Troponin I assay kit can 
Table 1. Patient characteristics
  Total population (N=157) NSTEMI (N=25) STEMI (N=33) NO ACS (N=99) 
Age (yr, mean±SD) 61.8±14.7 66.2±15.9 66.1±12.5 59.2±14.6 
Gender (N, men/women) 110/47 18/7 26/7 66/33 
BMI (kg/m2, mean±SD) 26.3±3.5 25.9±3.5 27±3.8 26.2±3.4 
hs-cTnI  (pg/mL, median [IQR]) 12.66 (6.25–44.09) 76.8* (16.35–150) 68† (14.94–279.05) 7.22*,† (5.24–14) 
sST2 ng/mL median (IQR) 28.20 (19–41.97) 33.70‡ (23.77–83.32) 25.30 (11.80–79.57) 26.90‡ (20.05–36.65) 
History of cardiovascular event (N)         
   Hypertension 76   14 14 48 
   Diabetes 44     7 13 24 
   Smoker 75   11 16 48 
   Family history 64     6 16 42 
TIMI SCORE (mean±SD) 5±1.75 4±2 4 ±1.44 2 ±1.29
   Home therapy (N) 
   Antiplatelets 39 100 98 20
   Nitroderivates 25   65 72 15
   Oral antidiabetics 28     7 12 30
   Beta blockers 31   22 11 40
   Insulin 23   54 31   8
   Statins 32   60 51 14
*P <0.0001; †P <0.0001; ‡P <0.04.
Abbreviations: NSTEMI, non ST segment elevation myocardial infarction; STEMI, ST elevation myocardial infarction; ACS, acute coronary syndrome; NO ACS, 
no acute coronary syndrome; BMI, body mass index; sST2, soluble isoform of suppression of tumoregenicity 2; hs-cTnI, high sensitive cardiac troponin I; 
TIMI score, thrombolysis in myocardial infarction score.
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detect troponin I in 96% of the reference population, and has a 
recommended 99th percentile cut-off of 26.2 pg/mL. The man-
ufacturer’s instructions also state a 99th percentile cut-off of 34.2 
pg/mL for men and 15.6 pg/mL for women [30].
3. Statistical analysis
Continuous variables are expressed as mean±SD or median 
(interquartile range [IQR]) according to whether the data followed 
a normal or non-normal distribution, respectively. Categorical 
variables are expressed as percentages (%). Statistical differ-
ences between groups were compared by using the chi-square 
test for categorical variables and the Student t-test or U Mann-
Whitney test for continuous variables. Univariate and multivari-
ate analysis were used to identify candidate variables for entry 
to a multivariable logistic regression model in order to select the 
variables most predictive of patient outcomes. We included the 
following variables of the patients’ baseline characteristics: body 
mass index (BMI), diabetes, family history of cardiovascular dis-
eases, age, onset time before ED presentation, tobacco smok-
ing, hypertension, thrombolysis in myocardial infarction (TIMI) 
score, log BNP, log copeptin, log NGAL, acute treatment, sST2, 
and hs-cTnI. Levels of sST2 and hs-cTnI were normalized by 
log transformation. Thus, the odds ratios (ORs) refer to a 10-fold 
increase in the levels of these markers. Receiver operating char-
Fig. 1.  Log hs-cTnI and sST2 median values in ACS and NO ACS patients and in STEMI, NSTEMI subgroups. (A) Log hs-cTnI value in NO 
ACS group vs ACS group, (B) Log hs-cTnI value in NSTEMI group vs STEMI group vs NO ACS, (C) Log sST2 value in NO ACS group vs 
ACS group, and (D) Log sST2 value in NSTEMI group vs STEMI group vs NO ACS. Bars represent the interquartile range, line in bars for 
median, and vertical lines represent the minimum and maximum value.
Abbreviations: ACS, acute coronary syndrome; NO ACS, no acute coronary syndrome; hs-cTnI, high sensitive cardiac troponin I; sST2, soluble isoform of an 
interleukin 1 receptor family member; NSTEMI, non ST segment elevation myocardial infarction; STEMI, ST elevation myocardial infarction.
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acteristic(ROC) curves were plotted, and the area under the curve 
(AUC) was estimated to demonstrate the optimal cut-off points 
of sST2 and hs-cTnI levels for prognosis evaluation on the basis 
of events and to establish appropriate sensitivity and specificity. 
P values of<0.05 from two-sided tests were considered signifi-
cant. All statistical analyses were performed by using Medcalc 
Table 2. Univariate and multivariate analyses in the total population and ACS patients only
Univariate
Total population 
OR 95% CI P Multivariate 
Total population 
OR 95% CI P
BMI 1.11 1.00–1.24 0.04 Log sST2 4.40 0.72–26.70 0.10
Age 1.02 0.99–1.05 0.12 Log hs-cTnI 0.98 0.41–2.33 0.96
Hypertension 1.94 0.85–4.45 0.11 TIMI score 1.52 1.06–2.20 0.02
Tobacco smoking 0.83 0.37–1.86 0.65 BMI 1.08 0.92–1.27 0.32
Diabetes  1.15 0.74–4.12 0.19 Log BNP 1.48 0.64–3.43 0.35
Family History of cardiovascular diseases 1.25 0.56–2.81 0.57
Log sST2 20.13 4.85–83.47 <0.0001
Log hs-cTnI 2.61 1.49–4.59 0.0008
Log BNP 2.02 1.10–3.73 <0.02
Log Copeptin 1.08 0.38–3.05 0.88
Log NGAL 0.66 0.16–2.79 0.58
TIMI score 1.53 1.16–2.02 0.002
Onset time before ED visit 0.99 0.98–1.00 0.46
Beta blockers 0.74 0.21–2.59 0.63
Antiaggregants 1.43 0.63–3.21 0.38
Nitroderivates 1.69 0.45–6.22 0.42
Oxygen 2.57 0.74–8.88 0.13
LMWH 2.05 0.82–5.14 0.12
Morphine 3.25 0.41–25.60 0.26
ACS patients  ACS patients
BMI 1.19 1.01–1.41 0.03 BMI 1.14 0.94–1.39 0.15
Age 1.03 0.99–1.07 0.08 Log sST2 12.10 2.31–63.25 0.003
Hypertension 2.41 0.79–7.28 0.11
Tobacco smoking 0.38 0.12–1.16 0.09
Diabetes  1.01 0.33–3.14 0.97
Family history of cardiovascular diseases 1.28 0.43–3.81 0.65
Log sST2 14.58 2.87–73.84 0.001
Log hs-cTnI 1.21 0.57–2.58 0.61
Log BNP 0.97 0.45–2.09 0.94
Log copeptin 1.19 0.37–3.84 0.76
Log NGAL 0.76 0.08–6.88 0.81
TIMI score 1.15 0.82–1.60 0.40
Onset time before ED visit 0.99 0.97–1.00 0.24
Beta blockers 0.81 0.17–3.77 0.79
Antiaggregants 1.09 0.37–3.18 0.87
Nitroderivates 1.02 0.21–4.97 0.97
Oxygen 1.22 0.26–5.66 0.79
LMWH 1.31 0.39–4.33 0.65
Morphine -- -- --
Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index; sST2, soluble isoform of suppression of tumoregenicity 2; hs-cTnI, high sensi-
tive cardiac troponin I; BNP, brain type natriuretic peptide; NGAL, neutrophil gelatinase-associated lipocalin; TIMI, thrombolysis in myocardial infarction; ED, 
emergency department; LMWH, low molecular weight heparin; ACS, acute coronary syndrome.
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version 12.1.4 software (Medcalc Software, Mariakerke, Belgium).
RESULTS
1. Distribution of the biomarkers
The median hs-cTnI [IQR] levels in the NO ACS and in the ACS 
groups are described in Fig. 1A. The median [IQR] hs-cTnI lev-
eld in NSTEMI patients and in the STEMI patients are described 
in Fig. 1B. The median sST2 [IQR] values in the NO ACS and in 
the ACS patients are described in Fig. 1C. In the NSTEMI and 
STEMI groups, the median (IQR) sST2 levels are described in 
Fig. 1D. There was no significant difference in sST2 levels be-
tween the STEMI group and the NO ACS group (P =0.72). By 
contrast, there was a significant difference in sST2 levels between 
the NSTEMI group and NO ACS group (P <0.04) (Fig. 1D). 
2. Prognostic results of the biomarkers
Considering the entire study population, of all clinical and de-
mographic characteristics, sST2 (OR 20.13, 95% confidence 
interval [CI] 4.85-83.47, P <0.0001) and hs-cTnI (OR 2.61, 95% 
CI 1.49-5.59, P =0.0008) independently predicted death at 30-
day follow-up along with BMI (OR 1.11) and TIMI score (OR 1.53) 
Fig. 2.  hs-cTnI and sST2 ROC curve analyses. (A) hs-cTnI ROC 
curve for prognostic 30-day mortality in total  patients; (B) sST2 
ROC curve for prognostic 30-day mortality in total patients; (C) 
hs-cTnI+sST2 combined ROC curve for prognostic 30-day mor-
tality in total patients. Red line represents the ROC curve, and 
grey lines represent the 95% confidence intervals. 
Abbreviations: AUC, area under the curve; sST2, soluble isoform of 
suppression of tumoregenicity 2; hs-cTnI, high sensitive cardiac tropo-
nin I; NPV, negative predictive value;  PPV, positive predictive value.
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in univariate analyses, and sST2 (OR 8.03, 95% CI 1.37-47.02, 
P =0.02) and TIMI score (OR 1.34, 95% CI 0.99-1.82, P =0.05) 
were the most predictive variables in the multivariate model (Ta-
ble 2). Univariate and multivariate regression analyses in ACS 
patients showed the high independent predictive power of only 
sST2 (univariate: OR 14.58; multivariate: OR 12.10) for the risk 
of cardiovascular events (Table 2). 
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Fig. 3.  hs-cTnI and sST2 ROC curve analyses in NSTEMI and STEMI patients. (A) hs-cTnI ROC curve for prognostic 30-day mortality in 
NSTEMI patients; (B) sST2 ROC curve for prognostic 30-day mortality in NSTEMI patients; (C) hs-cTnI ROC curve for prognostic 30-day 
mortality in STEMI patients; (D) sST2 ROC curve for prognostic 30-day mortality in STEMI patients. Red line represents the ROC curve, and 
grey lines represent the 95% confidence intervals.
Abbreviations: AUC, area under the curve; sST2, soluble isoform of suppression of tumoregenicity 2; hs-cTnI, high sensitive cardiac troponin I; NPV, nega-
tive predictive value; PPV, positive predictive value; NSTEMI, non ST segment elevation myocardial infarction, STEMI, ST elevation myocardial infarction.
3. ROC curve analysis for hs-cTnI and sST2
In the total population, the ROC curve for predicting the 30-day 
mortality with hs-cTnI and sST2 is described in Fig. 2A and B. 
In the total population, the predicted probability from the binary 
logistic model combining the two markers yielded an AUC of 
0.75 (95% CI 0.67-0.81, P <0.0001), which matched that of 
sST2 alone (Fig. 2C). Considering only the NSTEMI patients, the 
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hs-cTnI AUC for predicting the 30-day mortality was 0.75 (95% 
CI 0.52-0.91, P =0.01) and the sST2 AUC was 0.72 (95% CI 
0.49-0.89, P <0.05) (Fig. 3A, B). In the STEMI patients, the ROC 
curve AUC of hs-cTnI was 0.68 (95% CI 0.49-0.83, P =0.06) 
and that of sST2 was 0.80 (95% CI 0.62-0.92, P <0.001) (Fig. 
3C, D). 
4. hs-cTnI and sST2 in ACS patients
In ACS patients, the median (IQR) hs-cTnI level was 59.5 (17.5-
189) pg/mL in the no-events group and was 91.65 (16.35-150) 
pg/mL in the events group (P >0.05). The median (IQR) sST2 
value was 19.92 (11.29-45.54) ng/mL in the no-events group 
and was 77.8 (38.18-104.62) ng/mL in the events group (P < 
0.0005). Within the ACS patients, those in the STEMI group show ed 
a median (IQR) hs-cTnI level of 21 (10.32-81) pg/mL in the no-
events group and 101.55 (35.80-1104) pg/mL in the events 
group (P <0.02). In the same group, the median (IQR) sST2 
value was 18.7 (10.86-37.04) ng/mL in the no-events group 
and 80.86 (54.65-136.03) ng/mL in the events group (P <0.002). 
In NSTEMI patients, the median (IQR) hs-cTnI level was 144 
(35.98-240) pg/mL in the no-events group and was 76.8 (17.31 
-105.7) pg/mL in the events group (P =0.13). In the same group, 
the median (IQR) sST2 value was 25.4 (12.58-72.35) ng/mL in 
the no-events group and was 69.8 (48.02-101.87) ng/mL in the 
events group (P <0.05). 
5. Prognostic cut-off sST2 value in ACS patients
We considered the internationally recommended cut-off value of 
sST2 of 35 ng/mL, which is recognized as a prognostic factor in 
heart failure patients [26], and evaluated the events (i.e., deaths) 
on the basis of this cut-off. Among the STEMI patients in follow-
up (n=33), 16 patients had an sST2 value>35 ng/mL, and nine 
of these patients died during the 30-day follow up. By contrast, 
17 STEMI patients had an sST2 value<35 ng/mL, and only three 
of these patients died during follow up. In the univariate analy-
sis, an sST2 value>35 ng/mL in STEMI patients showed highly 
significant predictive power for the risk of events, with an OR of 
12.5 (95% CI 2.08-74.81, P =0.005). Among the NSTEMI pa-
tients in follow-up (n=22), nine patients had an sST2 value >35 
ng/mL and seven of these patients died during the 30-day fol-
low-up. Among the 13 NSTEMI patients with an sST2 value<35 
ng/mL, four patients died. In the univariate analysis, an sST2 
value>35 ng/mL showed low and non-significant predictive power 
for cardiovascular-related deaths in NSTEMI, with an OR of 3.06 
(95% CI 0.53-17.49, P =0.20).
DISCUSSION
In accordance with data from the literature, our study confirmed 
that in patients presenting to the ED with chest pain, sST2 has 
no significant distribution value for ACS [17, 23, 31]. This is con-
sistent with the fact that elevations of sST2 are not specific for 
acute myocyte cell death, but rather reflect a non-specific in-
flammatory response, as demonstrated in patients with asthma 
or autoimmune diseases [32]. Data from literature showed that 
BNP elevation in patients with ACS independently predicted the 
development of heart failure and all-cause mortality [33]. In our 
study, BNP was not predictive for ACS patients, although in the 
univariate analysis, BNP was predictive for cardiovascular events 
caused by the comorbidities presented in the study population.
Our data suggested that sST2 could be considered a powerful 
independent predictor for death within 30 days after admission, 
both in the total population presenting to the ED with chest pain 
and in ACS patients. The present results showed that in ED pa-
tients with chest pain, sST2 and hs-cTnI were independent pa-
rameters for predicting cardiovascular-related deaths at 30-day 
follow-up compared with the other parameters included in the 
univariate and multivariate analyses, such as BMI, diabetes, TIMI 
score, and family history of cardiovascular diseases (Table 2). 
To our knowledge, this predictive value of sST2 in patients with 
chest pain in the ED has not been described to date. This role 
could be linked to its better ability to reflect global cardiac stress 
compared with hs-cTnI. 
In ACS patients, the two biomarkers seem to be equally effec-
tive in predicting cardiovascular-related deaths within 30 days af-
ter ED admission. Both the univariate and multivariate analyses 
in this group of patients showed that the log sST2 value was the 
most powerful predictive biomarker, compared with the TIMI 
score and log hs-cTnI value. Previous studies demonstrated that 
in both STEMI and NSTEMI patients, the pre-discharge sST2 
level could serve as an independent predictive marker for the 
long-term risk of cardiovascular events [15, 34, 35]. Moreover, 
our study demonstrated that the sST2 level at ED admission could 
be a good prognostic marker for 30-day mortality in both STEMI 
and NSTEMI patients (Fig. 3B-D). Recent studies showed con-
trasting results on the prognostic role of sST2 in ACS patients [16, 
18, 31, 34]. One study showed that sST2 level increased in pa-
tients with ACS than in patients with stable coronary artery disease 
and without ACS, and that sST2 levels were associated with mor-
tality in patients with STEMI but not in patients with NSTEMI or 
stable angina [36]. Cytokines from damaged tissues may activate 
neighboring cells to produce sST2. sST2 has also been shown to 
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regulate the expression of proinflammatory cytokines from mac-
rophages, which may help prevent uncontrolled inflammatory re-
actions in myocardial infarction and are a prerequisite for healing 
and scar formation [22]. sST2 may contribute to this process and 
could be responsible for myocardial fibrosis and cardiac remod-
eling, which could affect prognosis after an episode of ACS [37].
To improve risk stratification of a patient with ACS in the ED, it 
is important to establish a standardized cut-off value of sST2. 
Some studies showed that heart failure patients with sST2 levels 
above a clinical threshold of >35 ng/mL have a much higher 
risk of mortality [26]. A recent study showed that NSTEMI pa-
tients are at a higher risk of adverse outcomes at 30 days when 
sST2 levels are above the cut-off value of 35 ng/mL [17]. Our 
study confirmed this finding; in fact, the sST2 cut-off value of 
35 ng/mL could distinguish the high number of patients that 
died within 30 days from those who were alive (no events) in 
both STEMI (OR 12.5) and NSTEMI (OR 3.06) patients. In the 
ED, establishment of a reliable cut-off value to identify a patient 
that is likely to suffer from a major cardiovascular event (i.e., death) 
in the short term after an episode of ACS is of fundamental rele-
vance to initiate the correct form of prevention and avoid adverse 
outcomes. Therefore, the aim of a physician should be not only 
stabilization of the patient but also achievement of an optimal 
sST2 value for reducing the risk of death. As stated by Richards 
et al [25], the greatest prognostic power is achieved when sST2 
levels are measured early in the post-infarction phase; therefore, 
blood samples should be acquired as soon as possible in the 
ED. In conclusion, in patients presenting to the ED with chest 
pain, the sST2 levels seem to have higher prognostic value for 
30-day cardiac mortality compared with hs-cTnI. In patients with 
ACS, sST2 assessment at ED arrival also seems to have greater 
prognostic value for 30-day cardiac death compared with hs-cTnI. 
Therefore, compared with hs-cTnI, sST2 seems to be a useful 
tool to immediately detect patients at high risk of death within 
30 days after hospital discharge in both STEMI and NSTEMI 
groups. The prognostic role of sST2 seems to increase when the 
cut-off value of >35 ng/mL is considered. Patients presenting to 
the ED with chest pain should be evaluated for sST2 levels im-
mediately in order to identify the subgroup of subjects for whom 
a more intensive treatment strategy should be considered to avoid 
the occurrence of short-term cardiovascular death.
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